Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.
Pardanani, A
Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. [electronic resource] - Leukemia 04 2018 - 1035-1038 p. digital
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Letter; Research Support, Non-U.S. Gov't
1476-5551
10.1038/leu.2017.330 doi
Adult
Aged
Aged, 80 and over
Benzamides--therapeutic use
Female
Humans
Janus Kinase 1--antagonists & inhibitors
Janus Kinase 2--antagonists & inhibitors
Male
Middle Aged
Primary Myelofibrosis--drug therapy
Protein Kinase Inhibitors--therapeutic use
Pyrimidines--therapeutic use
Thrombocytosis--drug therapy
Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. [electronic resource] - Leukemia 04 2018 - 1035-1038 p. digital
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Letter; Research Support, Non-U.S. Gov't
1476-5551
10.1038/leu.2017.330 doi
Adult
Aged
Aged, 80 and over
Benzamides--therapeutic use
Female
Humans
Janus Kinase 1--antagonists & inhibitors
Janus Kinase 2--antagonists & inhibitors
Male
Middle Aged
Primary Myelofibrosis--drug therapy
Protein Kinase Inhibitors--therapeutic use
Pyrimidines--therapeutic use
Thrombocytosis--drug therapy